ATH 0.00% 0.4¢ alterity therapeutics limited

Forebrain atrophy in early AD, by Masters et al, page-18

  1. 676 Posts.
    lightbulb Created with Sketch. 50
    Hi Skint,

    Thank you for your question, but it is a bit difficult to answer directly, given different theories and results from a number of studies and readings.

    But going of ATH434 results, iron deems to play a significant role in a number of neurodegenerate diseases.

    Regarding this and recent results, ATH434 has proven to be a proven and effective protectant of mitochondrial breakdown, and a reduction of iron overload, thus reducing iron aggregation, thus preventing neuoronal clumping and neuron degeneration, thus neuron cellular death and atrophy.

    More so with this, there has been evidence of neuron repair/improvement, along with other system improvement, such as the GIT, as seen in the mice studies when administered ATH434.

    Therefore, Iron seems to impact a signifcantly large portion of neuronal degeneration. Although, I feel it cannot be proven to point a finger at one given compound,such as iron, as you had mentioned, PB2T was shown to be an effective zinc chelator which showed to slow brain mass also, be it of a very small significance.

    Given that, there seems to be a number of other factors apart from just iron that may also cause brain mass reduction. But if iron is a major player, and protects mitchodrial destruction, we are on a winner.

    Regards.
 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Last
0.4¢
Change
0.000(0.00%)
Mkt cap ! $21.28M
Open High Low Value Volume
0.4¢ 0.4¢ 0.4¢ $203.0K 45.14M

Buyers (Bids)

No. Vol. Price($)
104 103311567 0.4¢
 

Sellers (Offers)

Price($) Vol. No.
0.5¢ 31829254 17
View Market Depth
Last trade - 10.53am 30/07/2024 (20 minute delay) ?
ATH (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.